At a glance
- Originator Ipsen
- Class Antineoplastics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Dec 2001 Discontinued-Preclinical for Cancer in France (Unknown route)
- 12 Feb 2001 Profile reviewed but no significant changes made
- 23 Oct 1997 No-Development-Reported for Cancer in France (Unknown route)